Business Wire Feed
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
– Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET – First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and more...
QT Imaging Announces Shipping Forty Breast Acoustic CT™ Scanners in 2025 and Meeting Its Revenue Guidance
Represents Year-Over-Year Revenue Growth of More than 285% Sales Increase Driven by Shipment of Forty Scanners in 2025, up from Twelve in 2024 Expects to End Year in a Strong Financial Position to Support Continued more...
Cizzle Brands Corporation Announces Closing of Transformative Transaction with the Acquisition of Flow Water Inc.’s Co-Manufacturing Business
The acquisition follows a spinout of the brand-related assets of the Target prior to closing, enabling Cizzle to focus on scaling Flow’s lucrative co-manufacturing business.TORONTO--(BUSINESS WIRE)--Cizzle Brands Corporation (Cboe Canada: CZZL) (the “Company” or “Cizzle”) more...
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) more...
Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease
- Italfarmaco grants JCR Pharmaceuticals exclusive rights to develop and commercialise givinostat in Japan - - Additional strategic collaboration in rare diseases aimed at enhancing both companies’ portfolios including exploring joint opportunities across JCR’s R&D more...
Inszone Insurance Services Expands Benefits Department in Michigan with Acquisition of Voyage Benefits, LLC
SACRAMENTO, Calif.--(BUSINESS WIRE)--#agencyacquisition--Inszone Insurance Services, a rapidly growing national provider of commercial, personal, and benefits insurance, is pleased to announce the acquisition of Voyage Benefits, LLC, a respected health and life insurance agency based in more...
New Outpatient Infusion Center Opening in Marietta, GA Expands the National Presence of Advanced Infusion Care
DALLAS--(BUSINESS WIRE)--Advanced Infusion Care (AIC), a division of AIS Healthcare and a leading provider of personalized infusion therapy, is pleased to announce the opening of another Advanced Infusion Care Center (AICC). This latest one is more...
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia
Deseyne® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia CorrectionBOCA RATON, Fla.--(BUSINESS WIRE)--The Cataltheia Group and its U.S. subsidiary, Bruno more...
14 Incheon Innovators Win 17 CES 2026 Innovation Awards
Announced ahead of CES 2026 by the show organizer, the Consumer Technology Association (CTA) Secured 17 awards, including Best of Innovation in Artificial Intelligence (AI). Incheon’s innovative companies recognized on the global stage for technological more...
BioMed Realty’s Sustainability Report Emphasizes Long-Term Commitment to Sustainable, Innovative Environments as Recognized by GRESB
SAN DIEGO--(BUSINESS WIRE)--BioMed Realty (“Company”), the largest privately owned operator of real estate for the life science and technology industries in the United States and the United Kingdom, today released its 2024 Sustainability Report, demonstrating more...
LivaNova to Present at J.P. Morgan Healthcare Conference in January
LONDON--(BUSINESS WIRE)--$LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and more...
FDA Approves Edwards Lifesciences’ SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and Drug Administration (FDA) approval for more...
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
Deep and durable responses observed in a heavily pretreated, historically immunotherapy-resistant population Findings reinforce the broad, pan-tumor activity of BOT+BAL across immunologically “cold” cancers LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology more...
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
The CTA No Objection Letter from Health Canada allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. The ALSTARS Trial is a phase 2, placebo-controlled study that includes clinical sites more...
Haven of Hope Commits to Expanding Life-Saving Adolescent Eating Disorder Care in Tennessee
MEMPHIS, Tenn.--(BUSINESS WIRE)--For more than a decade, Haven of Hope Eating Disorder Care Center has worked with individuals and families navigating the devastating realities of eating disorders—often stepping in when care is difficult to find, more...
AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today more...
American Heart Association (AHA) Scientific Sessions Highlights Report 2025: Indications, Companies, and Therapies Focus on GLP-1RAs, Hyperlipidemia, Heart Failure, Pulmonary Arterial Hypertension – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "American Heart Association (AHA): Scientific Sessions 2025 Highlights" report has been added to ResearchAndMarkets.com's offering. AHA 2025 took place in New Orleans, Louisiana, between 7-10 November 2025. The American Heart Association (AHA) Scientific more...
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
COBENFY is the first major advance in schizophrenia treatment in decades, offering a novel mechanism of action distinct from other therapies COBENFY has already been included in China’s national-level schizophrenia treatment guidelines, underscoring the urgent more...
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar – ARO-INHBE and ARO-ALK7 Interim Clinical Data – January 6, 2026 Type: more...
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and more...
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)--$ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, more...
Monroe Capital Supports InTandem Capital Partners’ Investment in The Phia Group
CHICAGO--(BUSINESS WIRE)--Monroe Capital LLC (“Monroe”) announced it acted as joint lead arranger on the funding of a senior credit facility to support the investment in The Phia Group (“Phia”) by private equity sponsor InTandem Capital more...
Kashiv BioSciences Secures INR 648 Crore Financing from Union Bank of India to Expand Manufacturing Facilities in Gujarat, India
The INR 648 crore facility will drive investment in state-of-the-art biologics manufacturing facility in Pipan, Gujarat The facility will enhance technical capabilities, improve global competitiveness, and create long-term, high-value employment across scientific, technical, and operational more...
Hope Biosciences Research Foundation Reports Promising Phase II Trial Results for Stem Cell Therapy in Parkinson’s Disease
SUGAR LAND, Texas--(BUSINESS WIRE)--#biopharma--Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ allogeneic adipose‑derived mesenchymal stem cell therapy (HB-adMSCs) for more...
Northwell to Launch Long Island’s First Pancreas Transplant Program
Northwell Transplant Institute is one of 59 adult transplant centers in the U.S. to offer heart, kidney, liver, lung and pancreas programsMANHASSET, N.Y.--(BUSINESS WIRE)--Northwell Health has received approval to launch Long Island’s first adult pancreas more...